Positron emission tomography imaging of small animals in anticancer drug development

Molecular Imaging and Biology

Volumn 7, Issue 1, 2005, Pages 53-58

  Aboagye, Eric O ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Anticancer; Drug development; PET; Small animal imaging

Indexed keywords

3 (2 FLUOROETHYL)SPIPERONE; ALKYLATING AGENT; AMIDE; ANTHRACYCLINE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; CARBON 11; CHOLINE; CYTOSTATIC AGENT; DNA; DNA TOPOISOMERASE; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GEFITINIB; GROWTH FACTOR; IODINE 124; LIPOCORTIN 5; NITROGEN 13; NUCLEOTIDE; OXYGEN 15; PYRROLE DERIVATIVE; TAXANE DERIVATIVE; TEMOZOLOMIDE; THYMIDINE DERIVATIVE; UNINDEXED DRUG; URACIL ARABINOSIDE; VINCA ALKALOID; VITRONECTIN RECEPTOR;

BIOASSAY; BIOLOGICAL ACTIVITY; CANCER THERAPY; CELL DEATH; CELL PROLIFERATION; DATA ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; GLUCOSE METABOLISM; IMAGE ANALYSIS; IMAGING SYSTEM; IN VITRO STUDY; IN VIVO STUDY; MEDICAL RESEARCH; MODULATION; MOLECULAR IMAGING; NONHUMAN; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; VALIDATION PROCESS; ANIMAL; DISEASE COURSE; DRUG EFFECTS; DRUG SCREENING; HUMAN; NEOPLASMS; PATHOLOGY; PROCEDURES;

ACUTE DISEASE; ADULT; ANTIMANIC AGENTS; BIPOLAR DISORDER; BRAIN; CONTRAST MEDIA; FEMALE; HUMANS; LITHIUM; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PYRIMIDINONES; RECEPTOR, SEROTONIN, 5-HT2A; VALPROIC ACID; ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; NEOPLASMS;

ANIMALIA;

EID: 25144466630     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-005-0886-2     Document Type: Review

References (37)

1. R Myers 2001 The biological application of small animal PET imaging Nucl Med Biol 28 585-593 10.1016/S0969-8051(01)00213-X 1:STN:280:DC%2BD3MvntValtQ%3D%3D 11516702
2. SP Hume R Myers 2002 Dedicated small animal scanners: A new tool for drug development Curr Pharm Des 8 1497-1511 1:CAS:528:DC%2BD38XkvVWksrs%3D
3. SP Hume RN Gunn T Jones 1998 Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals Eur J Nucl Med 25 173-176 10.1007/s002590050211 1:CAS:528:DyaK1cXhtVWisL4%3D 9473266
4. JY Qi RM Leary SR Cherry A Chatziioannou TH Farquhar 1998 High-resolution 3D Bayesian image reconstruction using the micro-PET small-animal scanner Phys Med Biol 43 1001-1013 10.1088/0031-9155/43/4/ 027
5. RJ Walledge AJ Reader EO Aboagye et al. 2002 4D PET with the quad-HIDAC: Development of dynamic list-mode EM image reconstruction IEEE Nucl Sci Symp Conf Rec 3 1716-1720 full text 10.1109/NSSMIC.2002.1239654 (Conference Proceeding)
6. DR Collingridge M Glaser S Osman et al. 2003 In vitro selectivity, in vivo biodistribution and tumor uptake of annexin V radiolabelled with a positron emitting radioisotope Br J Cancer 89 1327-1333 10.1038/ sj.bjc.6601262
7. 18F]Fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography Cancer Res 63 3791-3798 1:CAS:528:DC%2BD3sXltVGqs78%3D 12839975
8. EO Aboagye A Saleem PM Price 2002 Tumor imaging applications in the testing of new drugs In: BC Baguley DJ Kerr (eds) Anticancer drug development Academic Press San Diego 353-369
9. N Gupta P Price EO Aboagye 2002 PET for in vivo pharmacokinetic and pharmacodynamic measurements Eur J Cancer 38 2094-2107 10.1016/ S0959-8049(02)00413-6
10. LA Hammond L Denis U Salman et al. 2003 Positron emission tomography (PET): Expanding the horizons of oncology drug development Invest New Drugs 21 309-340 10.1023/A:1025468611547
11. EO Aboagye PM Price 2003 Use of positron emission tomography in anticancer drug development Invest New Drugs 21 169-181 10.1023/ A:1023521412787
12. EO Aboagye A Saleem V Cunningham S Osman P Price 2001 Extraction of 5-fluorouracil by tumor and liver: A non-invasive positron emission tomography study of patients with gastrointestinal cancer Cancer Res 61 4937-4941 1:CAS:528:DC%2BD3MXltVeqtLg%3D 11431319
13. JR Bading PB Yoo JD Fissekis et al. 2003 Kinetic modeling of 5-fluorouracil anabolism in colorectal adenocarcinoma: A positron emission tomography study in rats Cancer Res 63 3667-3674
14. 11 C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials Cancer Res 57 2172-2180
15. A Saleem J Yap S Osman et al. 2000 Modulation of fluorouracil tissue pharmacokinetics by eniluracil: In-vivo imaging of drug action Lancet 355 2125-2131 10.1016/S0140-6736(00)02380-1 1:CAS:528:DC%2BD3cXkvVWjtrk%3D 10902627
16. A Saleem RJ Harte JC Matthews et al. 2001 Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA; XR5000) in patients by positron emission tomography J Clin Oncol 19 1421-1429
17. OT DeJesus D Murali LG Flores et al. 2003 Synthesis of [F-18]-ZD1839 as a PET imaging agent for epidermal growth factor receptors J Label Compd Radiopharm 46 S1 10.1002/jlcr.750 (Abstract)
18. S Osman G Rowlinson-Busza SK Luthra et al. 2001 Comparative biodistribution and metabolism of carbon-11-radiolabeled N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and DNA-interacting analogs Cancer Res 61 2935-2944
19. K Spaepen S Stroobants P Dupont et al. 2003 [(18)F]FDG PET monitoring of tumor response to chemotherapy: Does [(18)F]FDG uptake correlate with the viable tumor cell fraction? Eur J Nucl Med Mol Imaging 30 682-688
20. HL Anderson JT Yap MP Miller et al. 2003 Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate J Clin Oncol 21 2823-2830 10.1200/JCO.2003.05.186
21. 18F]fluoro-2-deoxy-D-glucose Acta Oncol 39 629-637 10.1080/028418600750013320 1:STN:280:DC%2BD3M%2Fkt12ltg%3D%3D 11093372
22. 18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia J Nucl Med 40 1072-1079 1:CAS:528:DyaK1MXktVaqsLk%3D 10452326
23. M Glaser DR Collingridge EO Aboagye et al. 2003 Iodine-124 labelled annexin-V as a potential radiotracer to study apoptosis using positron emission tomography Appl Radiat Isotopes 58 55-62 10.1016/ S0969-8043(02)00239-7
24. 124I]iodinated-VG76e: A novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography Cancer Res 62 5912-5919 1:CAS:528:DC%2BD38XotFyktLo%3D 12384557
25. 18F-labeled RGD-containing glycopeptide and positron emission tomography Cancer Res 61 1781-1785 1:CAS:528:DC%2BD3MXit1Ohtbk%3D 11280722
26. T Groot-Wassink EO Aboagye M Glaser NR Lemoine G Vassaux 2002 Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene Hum Gene Ther 13 1723-1735 10.1089/104303402760293565 1:CAS:528:DC%2BD38XntlCqsLc%3D 12396625
27. SS Gambhir JR Barrio HR Herschman ME Phelps 1999 Assays for noninvasive imaging of reporter gene expression Nucl Med Biol 26 481-490 10.1016/ S0969-8051(99)00021-9
28. D Liu OC Hutchinson S Osman et al. 2002 Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin Br J Cancer 87 783-789 10.1038/sj.bjc.6600558
29. L Aloj C Caracó E Jagoda WC Eckelman RD Neumann 1999 Glut-1 and hexokinase expression: Relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture Cancer Res 59 4709-4714
30. J Boren M Cascante S Marin et al. 2001 Gleevec (3STI571) influences metabolic enzyme activities and glucose carbon flow towards nucleic acid and fatty acid synthesis in myeloid tumor cells J Biol Chem 276 37747-37753
31. JL Sherley TJ Kelly 1988 Regulation of human thymidine kinase during the cell cycle J Biol Chem 263 8350-8358 1:CAS:528:DyaL1cXkt1SqsLs%3D 3372530
32. JS Rasey JR Grierson LW Wiens PD Kolb JL Schwartz 2002 Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells J Nucl Med 43 1210-1217 1:CAS:528:DC%2BD38Xns1elsrk%3D 12215561
33. 3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines Nucl Med Biol 29 281-287 10.1016/S0969-8051(02)00286-X 11929696
34. AJ Fischman AA Bonab E Livni et al. 2003 Evaluation of a novel CDK2 inhibitor by microPET: A comparative study of FDG and FLT Mol Imaging Biol 5 157 (Abstract)
35. VJ Lowe JN Sarkaria BJ Kemp SM Geyer CD James 2003 Evaluation of EGFR therapy by FLT PET/CT imaging Mol Imaging Biol 5 160 (Abstract)
36. SJ Martin CP Reutelingsperger AJ McGahon et al. 1995 Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bcl-2 and Abl J Exp Med 182 1545-1556 10.1084/ jem.182.5.1545 1:CAS:528:DyaK2MXovFWqsL4%3D 7595224
37. FG Blakenberg J Tait K Ohtsuki HW Strauss 2000 Apoptosis: The importance of nuclear medicine Nucl Med Commun 21 241-250 10.1097/ 00006231-200003000-00008